Bank of New York Mellon’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $41.4M | Buy |
131,068
+11,665
| +10% | +$2.75M | 0.01% | 1191 |
|
|
2026
Q1 | $23.8M | Sell |
119,403
-2,862
| -2% | -$566K | ﹤0.01% | 1433 |
|
|
2025
Q4 | $23.1M | Sell |
122,265
-5,234
| -4% | -$1.01M | ﹤0.01% | 1460 |
|
|
2025
Q3 | $22.6M | Sell |
127,499
-607
| -0.5% | -$90.2K | ﹤0.01% | 1492 |
|
|
2025
Q2 | $14.6M | Buy |
128,106
+1,535
| +1% | +$164K | ﹤0.01% | 1689 |
|
|
2025
Q1 | $13.3M | Sell |
126,571
-3,421
| -3% | -$387K | ﹤0.01% | 1715 |
|
|
2024
Q4 | $13.9M | Sell |
129,992
-4,847
| -4% | -$548K | ﹤0.01% | 1752 |
|
|
2024
Q3 | $13.5M | Sell |
134,839
-11,151
| -8% | -$1.12M | ﹤0.01% | 1783 |
|
|
2024
Q2 | $12.3M | Sell |
145,990
-1,174
| -0.8% | -$93.4K | ﹤0.01% | 1853 |
|
|
2024
Q1 | $10.8M | Sell |
147,164
-8,395
| -5% | -$619K | ﹤0.01% | 1919 |
|
|
2023
Q4 | $11.1M | Buy |
155,559
+9,832
| +7% | +$580K | ﹤0.01% | 1928 |
|
|
2023
Q3 | $8.73M | Sell |
145,727
-6,142
| -4% | -$404K | ﹤0.01% | 2023 |
|
|
2023
Q2 | $10.9M | Buy |
151,869
+748
| +0.5% | +$56.1K | ﹤0.01% | 1909 |
|
|
2023
Q1 | $11.1M | Sell |
151,121
-5,712
| -4% | -$406K | ﹤0.01% | 1885 |
|
|
2022
Q4 | $10.5M | Sell |
156,833
-103,727
| -40% | -$6.74M | ﹤0.01% | 1914 |
|
|
2022
Q3 | $14M | Sell |
260,560
-3,393
| -1% | -$199K | ﹤0.01% | 1698 |
|
|
2022
Q2 | $14.7M | Sell |
263,953
-31,108
| -11% | -$1.77M | ﹤0.01% | 1716 |
|
|
2022
Q1 | $20.7M | Sell |
295,061
-12,178
| -4% | -$884K | ﹤0.01% | 1656 |
|
|
2021
Q4 | $29.6M | Buy |
307,239
+4,891
| +2% | +$452K | 0.01% | 1488 |
|
|
2021
Q3 | $26.3M | Sell |
302,348
-2,184
| -0.7% | -$169K | 0.01% | 1568 |
|
|
2021
Q2 | $24.9M | Buy |
304,532
+15,062
| +5% | +$1.25M | ﹤0.01% | 1605 |
|
|
2021
Q1 | $27.5M | Sell |
289,470
-26,488
| -8% | -$2.5M | 0.01% | 1516 |
|
|
2020
Q4 | $19.6M | Sell |
315,958
-18,510
| -6% | -$1.06M | ﹤0.01% | 1652 |
|
|
2020
Q3 | $19.9M | Sell |
334,468
-22,142
| -6% | -$1.51M | ﹤0.01% | 1478 |
|
|
2020
Q2 | $24.9M | Sell |
356,610
-18,155
| -5% | -$1.15M | 0.01% | 1306 |
|
|
2020
Q1 | $17M | Sell |
374,765
-52,571
| -12% | -$2.98M | 0.01% | 1398 |
|
|
2019
Q4 | $27.8M | Sell |
427,336
-55,026
| -11% | -$3.68M | 0.01% | 1377 |
|
|
2019
Q3 | $30M | Sell |
482,362
-67,582
| -12% | -$4.24M | 0.01% | 1272 |
|
|
2019
Q2 | $39.2M | Sell |
549,944
-2,732
| -0.5% | -$201K | 0.01% | 1116 |
|
|
2019
Q1 | $43.3M | Sell |
552,676
-100,284
| -15% | -$7.6M | 0.01% | 1046 |
|
|
2018
Q4 | $55.3M | Sell |
652,960
-145,699
| -18% | -$15.5M | 0.02% | 812 |
|
|
2018
Q3 | $137M | Sell |
798,659
-26,529
| -3% | -$4M | 0.04% | 483 |
|
|
2018
Q2 | $107M | Sell |
825,188
-7,514
| -0.9% | -$838K | 0.03% | 565 |
|
|
2018
Q1 | $85.8M | Sell |
832,702
-11,135
| -1% | -$1.1M | 0.02% | 677 |
|
|
2017
Q4 | $72.1M | Sell |
843,837
-141
| -0% | -$12.2K | 0.02% | 792 |
|
|
2017
Q3 | $71.7M | Sell |
843,978
-53,992
| -6% | -$4.28M | 0.02% | 768 |
|
|
2017
Q2 | $68M | Buy |
897,970
+11,614
| +1% | +$812K | 0.02% | 780 |
|
|
2017
Q1 | $58.5M | Buy |
886,356
+30,883
| +4% | +$2.03M | 0.02% | 858 |
|
|
2016
Q4 | $54.2M | Buy |
855,473
+77,034
| +10% | +$4.86M | 0.02% | 887 |
|
|
2016
Q3 | $49.6M | Sell |
778,439
-5,710
| -0.7% | -$419K | 0.01% | 894 |
|
|
2016
Q2 | $58.3M | Sell |
784,149
-161,337
| -17% | -$12M | 0.02% | 766 |
|
|
2016
Q1 | $63.2M | Buy |
945,486
+73,367
| +8% | +$4.46M | 0.02% | 754 |
|
|
2015
Q4 | $59M | Sell |
872,119
-108,681
| -11% | -$6.71M | 0.02% | 766 |
|
|
2015
Q3 | $52.4M | Buy |
980,800
+7,163
| +0.7% | +$435K | 0.02% | 813 |
|
|
2015
Q2 | $61.3M | Buy |
973,637
+361,467
| +59% | +$19.7M | 0.02% | 795 |
|
|
2015
Q1 | $29.4M | Buy |
612,170
+276,739
| +83% | +$10.6M | 0.01% | 1219 |
|
|
2014
Q4 | $11.1M | Sell |
335,431
-6,648
| -2% | -$216K | ﹤0.01% | 1853 |
|
|
2014
Q3 | $10M | Buy |
342,079
+14,291
| +4% | +$474K | ﹤0.01% | 1894 |
|
|
2014
Q2 | $12.7M | Buy |
327,788
+10,647
| +3% | +$432K | ﹤0.01% | 1771 |
|
|
2014
Q1 | $13.3M | Buy |
317,141
+10,697
| +3% | +$446K | ﹤0.01% | 1717 |
|
|
2013
Q4 | $10.1M | Buy |
306,444
+151,593
| +98% | +$4.94M | ﹤0.01% | 1883 |
|
|
2013
Q3 | $4.18M | Sell |
154,851
-21,311
| -12% | -$600K | ﹤0.01% | 2342 |
|
|
2013
Q2 | $4.11M | Buy |
+176,162
| New | +$3.17M | ﹤0.01% | 2315 |
|
Other funds holding LGND
CAM
CC
SIMG
RHJA
Bank of New York Mellon's LGND Position: Q2 2026 in Review
Bank of New York Mellon increased its Ligand Pharmaceuticals (LGND) stake by 9.8% in Q2 2026, buying an estimated $2.75M and bringing the position to 131,068 shares worth $41.4M. The position accounts for 0.01% of the portfolio, ranked #1191.
Bank of New York Mellon first reported a position in LGND in Q2 2013 and has held it in 53 quarters since. The position peaked at $137M in Q3 2018. 270 funds tracked by Wall St. Rank hold LGND as of Q2 2026.
- Bank of New York Mellon held 131,068 shares of Ligand Pharmaceuticals worth $41.4M as of Q2 2026.
- Bank of New York Mellon bought 11,665 Ligand Pharmaceuticals shares in Q2 2026, an estimated $2.75M.
- Ligand Pharmaceuticals made up 0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #1191 holding.
- Bank of New York Mellon first reported a position in Ligand Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
- Bank of New York Mellon's Ligand Pharmaceuticals position peaked at $137M in Q3 2018.
- 270 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.
Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.